Summary
Resveratrol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Breast Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Breast Cancer. ClinicalTrials.gov lists 3 registered trials linking Resveratrol to Breast Cancer: 2 have completed; 1 is terminated, withdrawn, suspended or of unknown status. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registration activity spans 2017 to 2019. The literature layer holds 8 publications for this pair: 1 meta-analysis, 3 systematic reviews and 4 clinical trial publications. Publication years run from 2012 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Breast Cancer ranks 1462 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous regression documented but rare (<0.5%); 5-year survival stage I: ~99%; stage IV: ~28% overall, improving with modern therapy.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 46.5 (trials 5.5, literature 21.0, tier 15, approved bonus 5.0) |
| Registered trials | 3 total: 0 recruiting, 0 active / not yet recruiting, 2 completed, 1 other |
| Linked publications | 8 (4 clinical trial publications, 3 systematic reviews, 1 meta-analysis) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | BRCA1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05306002 | Nutritional Intervention and DNA Damage of Patients With HBOC 2017 | completed | Not applicable | 34 |
| NCT03482401 | Disposition of Dietary Polyphenols and Methylxanthines in Mammary Tissues From Breast Cancer Patients 2017 | completed | Not applicable | 40 |
| NCT04266353 | Effect of Resveratrol on Serum IGF2 Among African American Women 2019 | withdrawn | Not applicable | — |
Published literature
- Systematic review The Relationship Between Climate Change and Breast Cancer and Its Management and Preventative Implications in South AfricaMahasa PS, Milambo MJP, Nkosi SF et al. · International journal of environmental research and public health · 2025 · PMID 41154889
- Systematic review Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies-An Update OverviewJakobušić Brala C, Karković Marković A, Kugić A et al. · Molecules (Basel, Switzerland) · 2023 · PMID 37175156
- Systematic review Endocrine disrupting chemicals and breast cancer: a systematic review of epidemiological studiesWan MLY, Co VA, El-Nezami H · Critical reviews in food science and nutrition · 2022 · PMID 33819127
- Clinical trial publication Disposition of Dietary Polyphenols in Breast Cancer Patients' Tumors, and Their Associated Anticancer Activity: The Particular Case of CurcuminÁvila-Gálvez MÁ, González-Sarrías A, Martínez-Díaz F et al. · Molecular nutrition & food research · 2021 · PMID 33939887
- Clinical trial publication Metabolic Profiling of Dietary Polyphenols and Methylxanthines in Normal and Malignant Mammary Tissues from Breast Cancer PatientsÁvila-Gálvez MÁ, García-Villalba R, Martínez-Díaz F et al. · Molecular nutrition & food research · 2019 · PMID 30690879
- Meta-analysis Sulforaphane and Epigallocatechin Gallate Restore Estrogen Receptor Expression by Modulating Epigenetic Events in the Breast Cancer Cell Line MDA-MB-231: A Systematic Review and Meta-AnalysisGianfredi V, Vannini S, Moretti M et al. · Journal of nutrigenetics and nutrigenomics · 2017 · PMID 29040973
- Clinical trial publication A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormonesChow HH, Garland LL, Heckman-Stoddard BM et al. · Journal of translational medicine · 2014 · PMID 25115686
- Clinical trial publication Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancerZhu W, Qin W, Zhang K et al. · Nutrition and cancer · 2012 · PMID 22332908
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Resveratrol approved for Breast Cancer?
Resveratrol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Breast Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Breast Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Resveratrol in clinical trials for Breast Cancer?
ClinicalTrials.gov lists 3 registered trials linking Resveratrol to Breast Cancer: 2 have completed; 1 is terminated, withdrawn, suspended or of unknown status. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registration activity spans 2017 to 2019.
What does the evidence show for Resveratrol in Breast Cancer?
Resveratrol has both completed registered trials and synthesis-level publications linked to Breast Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target BRCA1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.